Announces it has been selected to present the Company's scientific advancement of its key asset MB-204 titled MB-204: A Novel Adenosine A2a Antagonist for AD, ADHD and Depression at the Alzheimer's Association International Conference Sunday, July 16, 2023, being held in Amsterdam. "The adenosine A2a receptor (A2aR) is a very promising target for several neurological diseases, especially after the approval of Istradefylline, the first clinically approved A2aR antagonist for the treatment of Parkinson's disease," said Dr. Mark Williams, Chief Science Officer for Marvel. "Since the success of Istradefylline, the A2aR has become a promising target for treating other conditions such as Alzheimer's Disease, depression and attention deficit disorders amongst others." MB-204 is a fluorinated derivative of the U.S. FDA approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk for developing Parkinson's disease, Alzheimer's disease and improving concentration. Marvel Biosciences Corp shares V.MRVL are trading unchanged at $0.09.